EV71 induces COX-2 expression via c-Src/PDGFR/PI3K/Akt/p42/p44 MAPK/AP-1 and NF-κB in rat brain astrocytes
In Journal of Neuroinflammation, 2009
... PP1, AG1478, LY294002, SH-5, BQ-123, BQ-788, GP antagonist-2, GP antagonist-2A, U0126, SB202190, SP600125, and tanshinone IIA were from Biomol (Plymouth Meeting, PA) ... The structure and regulation of vinculinmore suppliers
In The Journal of Cell Biology, 2005
... The following antibodies were purchased: rabbit polyclonal anti–αE-catenin, mouse monoclonal anti-vinculin, rabbit polyclonal anti-myosin IIA and IIB, and rabbit polyclonal anti–l-afadin antibodies (Sigma-Aldrich); rabbit polyclonal anti-myosin IIB antibody (Covance); rabbit polyclonal anti-EGFP antibody (MBL); mouse monoclonal anti-EPLIN antibody ...
The relevance of JAK2 in the regulation of cellular transport.
Pristina, Serbia. In Curr Med Chem, Jan 2016
As a powerful regulator of transport mechanisms across the cell membrane, JAK2 regulates a wide variety of potassium, calcium, sodium and chloride ion channels, multiple Na+-coupled cellular carriers including EAAT1-4, NaPi-IIa, SGLT1, BoaT1, PepT1-2, CreaT1, SMIT1, and BGT1 as well as Na+/K+-ATPase.
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Oklahoma City, United States. In Consult Pharm, 2014
DATA SOURCES: A Medline search of English-language studies published between 2000 and March 2015 was conducted to identify pertinent papers using combinations of the following words: apixaban, atrial fibrillation, dabigatran, direct oral anticoagulant, edoxaban, factor IIa inhibitors, factor Xa inhibitors, mechanical heart valves, novel oral anticoagulant, rivaroxaban, venous thromboembolism, and warfarin.
Bortezomib-based treatment of acute antibody-mediated rejection: a case report.
More papers using
Beijing, China. In Genet Mol Res, 2014
At follow-up 6 months after bortezomib treatment, we observed: 1) serum creatinine stabilized at 130 μM from a peak level of 337 μM; 2) PRA decreased from a maximum of 66.7 to 0%; 3) blood plasma cell percentage rebounded after significantly decreasing following the first dose of bortezomib; 4) in renal allograft biopsy, immunohistochemical staining for C4d shifted from strongly positive to negative, and cellular rejection shifted from type IIA to borderline; and 5) adverse effects such as platelet suppression, hypotension, and grade 3 peripheral neuropathy emerged.
MAP kinases and cell migration
In Journal of Neuroinflammation, 2003
... BAPTA/AM, thapsigargin (TG), calmidazolium chloride (CaMI), KN-62, AG1296, LY294002, SP600125, and tanshinone IIA (TSIIA) were from Biomol (Plymouth Meeting, PA, USA) ...